Key takeaways
- FDA’s July 2026 review says there is insufficient clinical information to characterize Semax’s safety profile.
- In the human references FDA reviewed, most did not discuss safety; one reported no adverse events.
- FDA’s compounding risk list says compounded Semax “may pose risk for immunogenicity for certain routes of administration” and that FDA has “no, or limited, safety-related information” for the routes proposed.
- FDA’s briefing did not provide a common list of exclusions across the human studies; it notes that full information was unavailable for three meeting abstracts.
01Semax side effects at a glance
If you searched “semax side effects”, the clearest answer comes from what FDA’s 2026 review found, and from what it says it could not find.
| Source | What it records | What it cannot establish |
|---|---|---|
| FDA human-safety review, July 2026 | Most references did not discuss safety. One reported no adverse events. | A complete human safety profile or how often events occur. |
| FDA adverse-event review | One report from a consumer, in FDA’s search to 3 December 2025 (section 3). | That Semax caused the reported events or how frequently they occur. |
| FDA’s safety assessment | FDA said clinical information was insufficient to characterize Semax’s safety profile. | Whether an unreported event did or did not occur. |
These are reports about Semax as identified in the reviewed records. They do not establish that all products labelled Semax have the same contents or quality.
02What did human studies report?
FDA’s July 2026 briefing summarized eight references with human safety information. It reported that most did not discuss adverse events. The table shows the study year, the population and size FDA listed, and the safety information in its summary. These are human-study references, graded T2 here for the design information; the safety reporting is incomplete.
| Reference | Participants FDA listed | Safety information in FDA’s summary |
|---|---|---|
| Cherkasova, 2002 meeting abstract | Adults; FDA notes the number was not stated | Adverse events not discussed; full study information was unavailable. |
| Koroleva, 1996 | 37 adults | Authors reported no adverse events. |
| Kaplan, 1996 | 19 healthy adult men | Adverse events not discussed. |
| Ivanikov, 2002 | 32 adults | Adverse events not discussed. |
| Aminova, 2016 meeting abstract | 331 children | Adverse events not discussed; full study information was unavailable. |
| Proskurina, 2018 meeting abstract | 120 children aged 12–14 | Adverse events not discussed; full study information was unavailable. |
| Lebedeva, 2018 | 14 healthy adults | Adverse events not discussed. |
| Panikratova, 2020 | 14 healthy adults | Adverse events not discussed. FDA said it was unclear whether these participants were also in the 2018 reference. |
FDA’s broader count was 33–47 healthy adults, 69 adults with medical conditions, and 451 children across the references it reviewed. These figures are FDA’s grouped counts, not a new total across studies. FDA also noted that some references involved other medications or therapies, making Semax’s contribution to any effects difficult to determine.
“No adverse events reported” is not the same as a thorough finding of no risk. In most of these references, FDA said safety was not discussed. For three meeting abstracts, full study information was unavailable.
03What did FDA’s adverse-event review find?
FDA’s Office of Surveillance and Epidemiology searched the FDA Adverse Event Reporting System for Semax-related reports through 3 December 2025. It found one direct report from a consumer. The consumer reported ocular pain and eye burning after using a Semax-labeled product, reported hospitalization, and said the eye pain had not resolved when the report was made in May 2025.
FDA describes FAERS as containing “adverse event reports, medication error reports and product quality complaints resulting in adverse events that were submitted to FDA”, to support its post-marketing safety surveillance. Its briefing adds that compounders generally do not report adverse events to FDA, so FDA may not be aware of events that are never reported. FDA’s briefing records what the consumer reported; it does not report a finding that Semax caused the symptoms. One report also cannot show how often an event occurs. FDA’s two literature searches, covering records through 3 December 2025, found no human case reports of adverse events.
The report and the study findings are different kinds of evidence. A consumer report is a record of an event described to FDA. A study’s safety summary depends on what its authors measured and reported. Here, FDA said most study references did not discuss safety.
04What does FDA say about Semax safety?
FDA’s July 2026 briefing states that there is “insufficient clinical information to characterize the safety profile” of Semax. It also says Semax-related substances “may raise safety concerns.” FDA noted that most human references did not discuss safety, and that one reference discussed possible anti-thrombotic properties of Semax, which FDA said “raises concern about the risk of bleeding”. That is a regulator’s concern from the reviewed literature, not a measured rate of bleeding events in people.
Incomplete safety reporting
Most human references reviewed by FDA did not discuss adverse events. Missing reporting does not establish that no event occurred.
Unknown frequency
One consumer report and incomplete study reporting do not show how often an event occurs.
FDA’s compounding safety-risk page (content current as of 22 April 2026) separately says compounded Semax “may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities”, that FDA has “no, or limited, safety-related information for proposed routes of administration”, and that it “lacks sufficient information to know whether the drug would cause harm if administered to humans.” These statements address FDA’s information for compounded drugs; they do not describe a tested commercial product.
05Do FDA’s documents list who was excluded?
FDA’s briefing does not give a common list of exclusion criteria for the human references. It reports who was included in its safety summary, but that is not the same as a list of who was screened out. The exclusions for each individual study remain unclear from the FDA summary.
FDA says full information was unavailable for three meeting abstracts. It also says it was unclear whether the 14 people in the 2020 reference were the same participants as those in a 2018 reference. Those limits make it difficult to determine exactly who was represented across the records.
A safety review and a batch identity report answer different questions. For the separate question of what a lab report can establish about a tested sample, read how to read a COA.
06What we don’t know
- How often any reported event occurs.
- Whether the consumer-reported events were caused by Semax.
- What the human study references would show with complete safety reporting; most did not discuss safety, and three meeting abstracts lacked full information.
- A consistent list of study exclusion criteria across the references.
- Whether findings from those references apply to a particular product labelled Semax.
This is a plain-English summary of FDA documents checked on 21 November 2026. It is not medical advice.